Current Report Filing (8-k)
February 20 2020 - 4:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): February 20, 2020
AMPIO PHARMACEUTICALS,
INC.
(Exact name of registrant as specified
in Charter)
Delaware
|
|
001-35182
|
|
26-0179592
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification
No.)
|
373 Inverness Parkway, Suite 200
Englewood, Colorado 80112
(Address of principal executive offices, including zip code)
(720) 437-6500
(Registrant’s telephone
number, including area code)
Securities registered pursuant to
Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common
|
AMPE
|
NYSE American
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act
of 1934.
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive Agreement.
On February 20, 2020,
Ampio Pharmaceuticals, Inc. (the “Company,” “we,” or “our”) entered into
a Sales Agreement (“Sales Agreement”), with ThinkEquity, a division of Fordham Financial Management, Inc. (“ThinkEquity”)
and Roth Capital Partners LLC (“Roth”) (each of ThinkEquity and Roth, individually an “Agent”
and collectively, the “Agents”), to implement an “at-the-market” equity offering program under
which the Company may issue and sell from time to time shares of its common stock, par value $0.0001 per share, having an aggregate
offering price of up to $50,000,000 (the “Shares”) through the Agents, as our sales agents.
Subject to the
terms and conditions of the Sales Agreement, the Agents will use their commercially reasonable efforts to sell the Shares
from time to time, based upon the Company’s instructions. The Company has no obligation to sell any of the Shares, and
may at any time suspend sales under the Sales Agreement or terminate the Sales Agreement in accordance with its terms. The
Company has provided the Agents with customary indemnification rights, and the Agents will be entitled to an aggregate fixed
commission of 4.0% of the gross proceeds (2.0% to each Agent) from Shares sold.
Sales of the Shares
under the Sales Agreement will be made in transactions that are deemed to be “at-the-market offerings” as defined in
Rule 415 under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including
on the NYSE American market, at market prices or as otherwise agreed to with the Agents.
The description of
the Sales Agreement set forth herein does not purport to be complete and is qualified in its entirety
by reference to the full text thereof, which is attached hereto as Exhibit 10.1 and incorporated by reference
herein.
A Registration Statement
for the Shares has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on
April 20, 2017. This Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor
shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities law of any such state or jurisdiction.
Item 9.01 Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AMPIO PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Daniel G. Stokely
|
|
|
Daniel G. Stokely
|
|
|
Chief Financial Officer
|
Dated: February 20, 2020
Ampio Pharmaceuticals (AMEX:AMPE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ampio Pharmaceuticals (AMEX:AMPE)
Historical Stock Chart
From Sep 2023 to Sep 2024